Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 616 to 630 of 1561 results for do not do recommendations

  1. Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)

    Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    12 June 2024
    View recommendations

    Sections for TA983

  2. Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

    Evidence-based recommendations on guselkumab (Tremfya) for previously treated moderately to severely active Crohn's disease.

    Technology appraisal guidance
    Published
    28 August 2025
    View recommendations

    Sections for TA1095

  3. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.

    Technology appraisal guidance
    Published
    26 March 2025
    View recommendations

    Sections for TA1050

  4. What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    Recommendation ID CG184/4 Question What specialist management is effective for people whose symptoms do not respond to PPIs...

    Research recommendation
    Published
    15 November 2019

  5. What types of information provision, including mass-media campaigns, are effective and cost effective in preventing skin cancer in the UK? What factors influence effectiveness and cost effectiveness? •Does effectiveness and cost effectiveness vary for different population groups? (Groups could be defined by gender, age, race/ethnicity, socioeconomic status or other characteristics such as lifestyle and at-risk behaviours.) • What impact do they have on knowledge, attitudes, awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors that aid or hinder the success of these interventions or campaigns, including for different population groups? In particular, how does changing attitudes to sunbathing and tanning – and perceptions of the risk of skin cancer –influence success? Do attitudes vary for different population groups?

    Recommendation ID PH32/2 Question What types of information provision, including mass-media campaigns, are effective and cost effective

    Research recommendation
    Published
    9 June 2015

  6. Other specialist management:- What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    Recommendation ID CG184/4 Question Other specialist management:- What specialist management is effective for people whose symptoms...

    Research recommendation
    Published
    9 June 2015

  7. Additional assessments:- Do additional assessments (for IQ, language ability and motor ability) improve accuracy in diagnosing autism among preschool children (younger than 5 years) compared with signs and symptoms alone?

    Recommendation ID CG128/3 Question Additional assessments:- Do additional assessments (for IQ, language ability and motor...

    Research recommendation
    Published
    9 June 2015

  8. Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B (HST32)

    Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.

    Highly specialised technologies guidance
    Published
    2 April 2025
    View recommendations

    Sections for HST32

  9. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA766

  10. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA882

  11. Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA245

  12. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 June 2014
    View recommendations

    Sections for TA315

  13. Renal replacement therapy services for adults (QS72)

    This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    3 October 2018
    View quality statements

    Sections for QS72

  14. What is the clinical and cost effectiveness of fitting amplification devices(s) in people with tinnitus who have hearing loss but no perceived hearing difficulties?

    Recommendation ID NG155/12 Question What is the clinical and cost effectiveness of fitting amplification devices(s) in people with...

    Research recommendation
    Published
    17 March 2020

  15. Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical outcomes in women who choose and women who do not choose to have risk-reducing surgery. [new 2013]

    Recommendation ID CG164/5 Question Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical

    Research recommendation
    Published
    9 June 2015